Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study

Jacoba M. Maurer; Susan Hofman; Reinout C. A. Schellekens; Wouter F. Tonnis; Annelien O. T. Dubois; Herman J. Woerdenbag; Wouter L. J. Hinrichs; Jos G. W. Kosterink; Henderik W. Frijlink

doi:10.1016/j.ijpharm.2016.03.027

Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study

Jacoba M. Maurer^*, Susan Hofman, Reinout C. A. Schellekens, Wouter F. Tonnis, Annelien O. T. Dubois, Herman J. Woerdenbag, Wouter L. J. Hinrichs, Jos G. W. Kosterink, Henderik W. Frijlink

^*Corresponding author voor dit werk

Onderzoeksoutput › Academic › peer review

31 Citaten (Scopus)

Samenvatting

The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5 mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I: (C) 2016 Elsevier B.V. All rights reserved.

Originele taal-2	English
Pagina's (van-tot)	175-186
Aantal pagina's	12
Tijdschrift	International Journal of Pharmaceutics
Volume	505
Nummer van het tijdschrift	1-2
DOI's	https://doi.org/10.1016/j.ijpharm.2016.03.027
Status	Published - 30-mei-2016

Toegang tot document

10.1016/j.ijpharm.2016.03.027

Handle.net

Permanente koppeling

Document onder embargo

Development and potential application of an oral ColoPulse
Final publisher's version, 1,36 MB

Citeer dit

Maurer, J. M., Hofman, S., Schellekens, R. C. A., Tonnis, W. F., Dubois, A. O. T., Woerdenbag, H. J., Hinrichs, W. L. J., Kosterink, J. G. W., & Frijlink, H. W. (2016). Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study. International Journal of Pharmaceutics, 505(1-2), 175-186. https://doi.org/10.1016/j.ijpharm.2016.03.027

@article{903547536c7d4886baf6d6534f8a0257,

title = "Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study",

abstract = "The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5 mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I: (C) 2016 Elsevier B.V. All rights reserved.",

keywords = "Infliximab, Colon specific delivery, Oral delivery, ColoPulse, Crohn's disease, Protein stability, Formulation, CROHNS-DISEASE, LOCAL INJECTION, STABILITY, PROTEINS, BIOAVAILABILITY, STABILIZATION, ANTIBODIES, BEHAVIOR, GLASSES, INULIN",

author = "Maurer, {Jacoba M.} and Susan Hofman and Schellekens, {Reinout C. A.} and Tonnis, {Wouter F.} and Dubois, {Annelien O. T.} and Woerdenbag, {Herman J.} and Hinrichs, {Wouter L. J.} and Kosterink, {Jos G. W.} and Frijlink, {Henderik W.}",

year = "2016",

month = may,

day = "30",

doi = "10.1016/j.ijpharm.2016.03.027",

language = "English",

volume = "505",

pages = "175--186",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier Bedrijfsinformatie b.v.",

number = "1-2",

}

Maurer, JM, Hofman, S, Schellekens, RCA, Tonnis, WF, Dubois, AOT, Woerdenbag, HJ , Hinrichs, WLJ , Kosterink, JGW & Frijlink, HW 2016, 'Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study', International Journal of Pharmaceutics, vol. 505, nr. 1-2, blz. 175-186. https://doi.org/10.1016/j.ijpharm.2016.03.027

TY - JOUR

T1 - Development and potential application of an oral ColoPulse infliximab tablet with colon specific release

T2 - A feasibility study

AU - Maurer, Jacoba M.

AU - Hofman, Susan

AU - Schellekens, Reinout C. A.

AU - Tonnis, Wouter F.

AU - Dubois, Annelien O. T.

AU - Woerdenbag, Herman J.

AU - Hinrichs, Wouter L. J.

AU - Kosterink, Jos G. W.

AU - Frijlink, Henderik W.

PY - 2016/5/30

Y1 - 2016/5/30

N2 - The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5 mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I: (C) 2016 Elsevier B.V. All rights reserved.

AB - The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5 mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I: (C) 2016 Elsevier B.V. All rights reserved.

KW - Infliximab

KW - Colon specific delivery

KW - Oral delivery

KW - ColoPulse

KW - Crohn's disease

KW - Protein stability

KW - Formulation

KW - CROHNS-DISEASE

KW - LOCAL INJECTION

KW - STABILITY

KW - PROTEINS

KW - BIOAVAILABILITY

KW - STABILIZATION

KW - ANTIBODIES

KW - BEHAVIOR

KW - GLASSES

KW - INULIN

U2 - 10.1016/j.ijpharm.2016.03.027

DO - 10.1016/j.ijpharm.2016.03.027

M3 - Article

C2 - 26997425

SN - 0378-5173

VL - 505

SP - 175

EP - 186

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

IS - 1-2

ER -

Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study

Samenvatting

Toegang tot document

Handle.net

Document onder embargo

Vingerafdruk

Citeer dit